Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
| ▸ | TIPARP | Q7Z3E1 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24717955 | 0.72 | MEN1 (0.37) | MAPTKDM4CGAAALDH1A1 | |
| SCHEMBL20128645 | 0.71 | CYP11B2 (0.40) | MAPTKDM4CTIPARPALDH1A1 | |
| SCHEMBL17169684 | 0.64 | ALDH1A1 (0.43) | MAPTKDM4CGAAALDH1A1 | |
| SCHEMBL23918999 | 0.64 | MAPT (0.35) | MAPTKDM4CGAA | |
| SCHEMBL21477111 | 0.62 | MAPT (0.35) | MAPTKDM4CGAAALDH1A1 | |
| SCHEMBL20231586 | 0.62 | MAPT (0.35) | MAPTKDM4CGAA | |
| SCHEMBL20128636 | 0.61 | MAPT (0.39) | MAPTKDM4C | |
| SCHEMBL23350017 | 0.59 | MAPT (0.35) | MAPTKDM4CGAA | |
| SCHEMBL20231587 | 0.59 | MAPT (0.37) | MAPTKDM4CGAAALDH1A1 | |
| SCHEMBL20128655 | 0.58 | MAPT (0.39) | MAPTKDM4CGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200038513-A1 | MODULATORS OF FAK PROTEOLYSIS AND ASSOCIATED METHODS OF USE | YALE UNIVERSITY | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200038513-A1 | MODULATORS OF FAK PROTEOLYSIS AND ASSOCIATED METHODS OF USE | PTK2, CTTN, CRBN | MAPT 2238/4885KDM4C 3739/4885TIPARP 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.